Stellar V Capital Corp. (Cayman Islands)

For redemption/deadline tracking, the filing pins the mandatory liquidation date and trust value: if no deal closes by October 31, 2026, public shareholders are to receive trust proceeds and the warrants expire worthless. It also discloses only $618,759 of cash outside trust and says its liquidity condition raises substantial doubt about going concern, while the filing's March 31, 2025 redemption value is $10.13 per share, not $10.63. The company remains a shell with no identified target.

The filing establishes the baseline financial position and trust value ($10.07 per share at IPO, potentially growing with interest), confirms the redemption mechanics and deadline, and provides details on sponsor incentives and conflicts. It is essential for tracking the SPAC's progress toward a deal and for evaluating redemption risks.

This administrative milestone transitions the SPAC’s securities from bundled units to distinct equity and derivative components, which typically broadens the holder base, improves liquidity, and clarifies valuation metrics for both the shares and warrants before a target acquisition. While the filing does not modify the Oct 31, 2026 redemption deadline or adjust the trust account composition, the independent listing of SVCC and SVCCW enables market participants to price risk and leverage separately, influencing arbitrage flows and signaling sponsor activity levels during the “SEARCHING” phase. Investors tracking capital deployment should monitor post-separation trading volume and optionality pricing as proxies for institutional confidence or speculative hedging ahead of any merger announcement.

The reported $151,050,000 trust balance and $10.07 per-share valuation permanently set the baseline liquidity and maximum pro-rata redemption price for public shareholders through the 21-month deadline. The $5,250,000 deferred underwriting liability acts as a structural incentive, ensuring underwriters only collect their fee upon a successful deal closure, while simultaneously defining the exact amount excluded from initial redemption calculations. Because the Company explicitly notes it has not yet commenced operations or identified any target business, the filing contains zero claims regarding customers, operating revenue, market size, strategy execution, technology, or partnerships. Instead, the substantive record focuses entirely on pre-combination governance: founder share lock-up conditions, a $300,000 repaid working capital promissory note, and up to $1,500,000 in uncommitted future working capital loans available from the Sponsor or founding team. Tracker attention should now shift exclusively to future filings announcing target discovery, definitive agreements, proposed extensions, or large-scale redemption events that test the trust's remaining interest yield against the disclosed monthly administrative and professional burn rates.

This filing establishes the trust value, the redemption mechanics, and the deadline for SVCC's business combination. There are no new terms for the ongoing search, but the trust value per share ($10.07) and the 21-month deadline (October 31, 2026) are now definitive for investors.

The reported transaction reflects sponsor/insider capital deployed at prevailing market prices rather than against trust account proceeds, which may signal management alignment during the SEARCHING phase but does not mechanically alter shareholder redemption rights, extension voting procedures, or trust distribution mechanics. The filing contains no assertions regarding customer pipelines, revenue targets, market size estimates, technology roadmaps, partnership agreements, ongoing litigation, or executive personnel shifts. The sole operational claim—the share accumulation and resulting ownership stake—originates entirely from the Form 4 submission by Prokopios Akis Tsirigakis.

Per the filing’s own disclosure, the open‑market acquisition shows that a founding officer allocated personal capital to the public equity rather than using private placements, avoiding any trust restructuring or dilution mechanisms. For investors tracking sponsorship behavior and redemption mechanics, this confirms increased insider exposure while the SPAC hunts for a target, but it does not alter any contractually scheduled redemption windows, extension votes, or trust distributions. The document contains no assertions regarding customers, revenue, market size, strategy, technology, partnerships, or litigation. The only operative update is the reported share count; continued Form 4 monitoring will clarify whether this reflects a deliberate accumulation trend as the October 31, 2026 deadline approaches.

Management asserts that the founders’ near-nominal $25,000 equity purchase creates asymmetric incentives compared to the $10.00 public offering price, a structural conflict the filing notes could motivate the completion of unprofitable targets—a risk the issuer emphasizes via extensive dilution warnings and net tangible book value tables showing up to 107% dilution under maximum redemption scenarios. The $10.07 per-share trust floor and $100,000 maximum liquidation expense deduction establish the precise redemption payout parameters cited by the sponsor and governing documents.

For investors monitoring redemption calendars and trust liquidation triggers, stripping the 30-day cure period tightens the mechanical window between missed deadlines and forced cash returns, ensuring sponsor funding demands cannot delay shareholder redemptions. The explicit 21-month cap removes ambiguity around extension timing, while the newly inserted risk disclosures increase transparency regarding execution uncertainty and potential dilution without altering underlying economics or target strategy.

This filing provides the final prospectus for the SPAC IPO, detailing the offering size (15,000,000 units at $10.00 each), trust account ($151,050,000 initially, $10.07 per share), deadline (21 months from closing), redemption rights, sponsor and management background, risk factors, and the terms of the warrants. It also includes the agreements that govern the sponsor's lock-up, private placements, and registration rights. For investors, this is the key document to evaluate the SPAC's structure and potential.

The division’s review directly impacts redemption mechanics and trustee payout timing by highlighting unresolved conflicts between the “30-day cure period,” the “10-day loan funding period,” and the statutory mandate to return shareholder funds promptly if an initial business combination is not completed within the completion window. If sponsor or affiliates ultimately fail to provide the required loans, the staff demands clarification on how this failure alters the cure period and protects shareholders during potential liquidation scenarios.

This registration defines the key terms for investors: trust value per share ($10.025), deadline (18 months from IPO closing), extension mechanism (sponsored deposit), and sponsor incentives (founder shares at nominal cost). It establishes the framework for future business combination, redemptions, and potential conflicts of interest.

For investors monitoring redemption calendars, capital preservation, and sponsor alignment, the prospectus establishes that the trust is funded at $10.05 per unit, defining the baseline pro-rata cash return upon liquidation or extension redemptions, while the registrant’s own dilution analysis warns of immediate net tangible book value dilution of up to $10.76 per public share at maximum redemption thresholds.

These adjustments matter because they establish the precise contractual and exchange-rule boundaries governing early trust fund deployment versus the expiration date, which directly shapes investor liquidity timelines and redemption window parameters. By clarifying that non-managing sponsor members hold no veto authority, face no mandatory retention rules, yet structurally benefit from deal approval, investors can better assess sponsor voting behavior and fiduciary conflict management during merger ballots. Expanded Competition disclosures acknowledging aggressive rivalry among other SPACs and detailed Anti-Dilution and Private Warrant conversion mechanics provide the framework investors will use to project post-merger equity distribution and negotiation leverage. The filing contains no reported data on customers, recurring revenue, total addressable market size, proprietary technology roadmaps, strategic partnerships, ongoing litigation, or named executive compensation tables; it functions exclusively as a prospectus drafting revision to clear SEC staff review ahead of the registration statement’s effectiveness.

This correspondence confirms the SEC is actively reviewing SVCC’s proposed capital structure and governance controls ahead of a definitive S-1 filing. The trust release inquiry may force narrower, more objective distribution language, which would directly constrain early redemption pathways and preserve trust value until formal business combination votes occur. Scrutiny of non-managing sponsor agreements and voting incentives highlights regulatory concern that deeply discounted sponsor equity could accelerate merger approvals misaligned with public shareholder exits.

Investors monitoring trust mechanics receive direct confirmation that early trust distributions are contractually tethered to charter amendments—a structural guardrail that reduces near-term liquidity uncertainty but signals minimal willingness to alter corporate governance for early exits. The explicit revision of extension limits beyond twenty-four months directly informs the redemption calendar and deadline pressure. By forcing tighter transparency on sponsor-aligned voting obligations, founder share transfer rights, and the concentrated economics available to non-managing sponsor participants, the filing reshapes the anticipated voting calculus at any future shareholder meeting. The capped $1,500,000 convertible working capital facility introduces a defined, limited dilution scenario that management can deploy without triggering broader equity raises, while the unsettled parameters around sponsor-side institutional participation leave open how sponsor-affiliate leverage could influence deal approval versus holder redemption patterns. The continued SEC comment cycle confirms the company remains in the searching phase, but the substantive disclosure updates materially refine how investors can model redemption thresholds, extension risk, and sponsor conduct ahead of a target announcement.

This letter suspends the registration process until revisions satisfy staff requirements, directly preserving the $10.63 per-share trust value through the October 31, 2026 deadline while clarifying the actual mechanics of redemption eligibility and sponsor liquidation preferences. Resolving the Nasdaq trust-deposit consistency, voting contradiction reconciliation, and founder share transfer exceptions establishes whether the sponsor’s economics inherently pressure public shareholders toward a combination or allow orderly exits.

The filing structures investor risk around the sponsor’s nominal $0.006 per-share founder equity cost versus the public’s $10.00 per-unit price, with the prospectus’s own dilution tables projecting immediate decreases in pro forma net tangible book value ranging from $(0.97) to $(1.00) per share under maximum redemption assumptions. Because the trust account initially holds $10.00 per share, the document highlights that creditor claims could potentially reduce actual distribution amounts below that anticipated threshold, despite the sponsor’s indemnification agreement to cover shortfalls.

What changed: Annual Report on Form 10-K for fiscal year ended December 31, 2025, filed by Stellar V Capital Corp. (SVCC), a blank-check company still searching for a business combination target. This is SVCC's first annual report since its January 2025 IPO. Trust account grew to $156.7 million ($10.45 per public share) from $151.1 million placed at IPO ($10.07 per share), reflecting $5.7 million of interest income. No target has been selected; management reports no substantive discussions with any candidate. Harry Braunstein, an independent director, died in November 2025; his son Michael Braunstein was appointed director in February 2026. Net income of $5.3 million for 2025 (all from trust interest). Cash on hand $354,108, working capital $320,514. The company's go‑concern disclosure flags substantial doubt if it cannot complete a business combination by its October 31, 2026 deadline. Why it matters: Trackers now have a baseline trust value of ≈$10.45/share (above the typical $10.00 redemption floor) and a clear deadline of October 31, 2026. The lack of any identified target or substantive discussions, combined with the go‑concern warning, heightens the risk of liquidation if a deal is not announced soon. The board change (independent director replaced by founder’s son) may affect governance and sponsor oversight.

What changed: A Form 8-K current report disclosing a routine board succession event under Item 5.02 following the passing of a founding director. According to the filing, the Board elected Michael Braunstein as a Class II director effective February 28, 2026, filling the vacancy created by the November 2, 2025, passing of his father, former board member Harry Braunstein. The Board determined Michael Braunstein meets NASDAQ Stock Market independence standards. He will serve on the Audit Committee and the Compensation Committee, and chair the Nominating and Corporate Governance Committee. His documented background includes partner at Braunstein Turkish LLP since September 2009, managing member of Sunset Capital 1 LLC and affiliate entities since November 2025, president of those entities from January 2024 to November 2025, vice president from January 2019 to December 2023, and director of Sunset Capital 1 LLC. He holds a bachelor degree in music business from New York University in 2004 and a Juris Doctor degree from Brooklyn Law School in 2009. Co-Chief Executive Officer Prokopios (Akis) Tsirigakis executed the report on March 4, 2026. Why it matters: The succession maintains board quorum and full committee staffing ahead of the October 31, 2026 termination deadline, preventing delays to shareholder redemption windows, extension meetings, or trust accounting procedures. Appointing a family member signals continuity in sponsor oversight rather than an immediate strategic pivot, yet because the registrant remains in SEARCHING status with no merger targets, financial projections, or market size claims disclosed, the practical effect is purely compliance-driven. Investors should track subsequent filings for any amended prospectuses, trustee updates, or acquisition announcements.

What changed: A Schedule 13G/A amendatory statement reporting changes in beneficial ownership by the Healthcare of Ontario Pension Plan Trust Fund. The excerpt names only the reporting holder and confirms the filing type. It discloses no adjusted aggregate shares acquired, percentage of class, acquisition date, sole or shared voting or investment power, or statement of purpose. Consequently, it contains no data touching the $10.63 public trust per share metric, the October 31, 2026 business combination deadline, any proposed extensions, redemption mechanics, or sponsor conduct. Why it matters: Although the text supplies no share counts or price references to recalibrate investor expectations around the $10.63 trust value or the 2026-10-31 search window, the amendment’s mere existence signals that the Healthcare of Ontario Pension Plan Trust Fund either crossed a reporting threshold or altered its voting or investment posture. In a SEARCHING-stage SPAC where no announced target exists, unreported block movements frequently precede activist engagement, lock-up negotiations, or quiet accumulation ahead of a de-SPAC vote. Investors monitoring the deadline should treat the absence of disclosed numbers as a neutral-to-waiting posture until the full exhibit (SEC accession number 0001193125-26-051256) reveals whether the trust fund is hedging, increasing exposure, or preparing to redeem against the $10.63 trust per share benchmark before the 2026-10-31 cutoff.

What changed: Quarterly report on Form 10-Q for the period ended September 30, 2025, filed by Stellar V Capital Corp., a blank-check company still searching for a business combination. The trust account balance increased to $155,213,505 from $151,050,000 at IPO, driven by $4,163,505 in interest earned. Cash and working capital are $424,623 and $417,829, respectively. The company reported a net income of $3,914,405 for the nine months. No business combination has been announced, no redemptions occurred, and the liquidation deadline remains October 31, 2026. The over-allotment option expired unexercised. Why it matters: This filing confirms the SPAC is still in its search phase, with adequate trust proceeds and a clear deadline. The trust value per share is $10.35 (as of September 30, 2025), slightly above the IPO price, indicating no redemptions and positive interest. Investors should note the going concern doubt if no deal is completed by October 2026, but management plans to find a target before then.

What changed: Form 8-K Current Report disclosing a director departure under Item 5.02, specifically announcing the death of Board member Mr. Harry Brausnstein. According to the filing signed by Co-Chief Executive Officer Prokopios (Akis) Tsirigakis, Mr. Harry Brausnstein passed away on November 2, 2025, and the company learned of the death on November 6, 2025. Mr. Brausnstein had served on the Board since January 29, 2025, as chair of the Nominating and Corporate Governance Committee and as a member of both the Audit Committee and the Compensation Committee. The report states the Board will review its committee composition and overall membership in due course in accordance with the company’s amended and restated memorandum and articles of association. No other operational, financial, or contractual updates are reported. Why it matters: This filing does not amend the redemption schedule, adjust the trust account value per share, extend the liquidation deadline, or signal progress toward a merger or business combination. The vacancy created by the director’s death requires the board to fill seats on three separate committees, but the filing provides no timeline for appointments, nor does it trigger extension mechanisms, warrant repricing, or shareholder votes. As attributed by the Co-Chief Executive Officer, committee realignment will occur internally per the corporate charter. Redemption rights and termination mechanics remain unaffected pending any future charter amendments or successor appointments.

What changed: Amended Schedule 13G beneficial ownership report. The filing amends a prior institutional holdings disclosure on behalf of AQR Capital Management, LLC; AQR Capital Management Holdings, LLC; and AQR Arbitrage, LLC. The provided excerpt does not contain revised share quantities, percentage of class, acquisition dates, or investment purpose statements typically required to detail the nature of the change. Why it matters: Schedule 13G/A filings serve as the primary public record of institutional equity positions that can influence voting leverage and redemption liquidity in a SPAC. This submission confirms that the listed AQR entities remain registered holders of SVCC securities, but because the excerpt discloses no numerical stakes, purchase timelines, or strategic intent, it cannot be determined whether the amendment reflects portfolio consolidation, passive index maintenance, or arbitrage positioning ahead of the October 31, 2026 search deadline or a forthcoming business combination.

What changed: Quarterly report on Form 10-Q for the period ended June 30, 2025, filed by Stellar V Capital Corp. (SVCC), a blank-check company (SPAC) still searching for a business combination target. Trust account value rose to $153,603,825 ($10.24 per share) from $151,050,000 ($10.07 per share) at IPO, due to $2,553,825 in interest income. No business combination announced. The company continues to search for a target with a deadline of October 31, 2026. Cash balance is $484,043 with working capital surplus of $509,998. The company discloses substantial doubt about its ability to continue as a going concern. Why it matters: For investors monitoring redemption value and timeline, the trust per-share value increased to $10.24, providing a modest buffer above the $10.00 IPO price. The deadline remains October 31, 2026, with no extension announced. The going concern disclosure highlights the need for a deal or additional financing. No sponsor conduct issues or deal progress reported.

What changed: A Form 10-Q quarterly report filed May 15, 2025 — Stellar V Capital Corp.'s first quarterly report since its January 31, 2025 IPO. It is not a merger agreement or target announcement; it contains unaudited financials, MD&A, and controls disclosures for a Cayman blank-check shell company still searching. The 10-Q reports the post-IPO state as of March 31, 2025: the trust account was funded with $151,050,000 at the IPO and totaled $152,014,025 at quarter-end, a redemption value of $10.13 per public share; the underwriters' over-allotment option expired unexercised on March 17, 2025; the sponsor promissory note was repaid; and no target or definitive business-combination agreement is disclosed. Management restates the 21-month completion window ending October 31, 2026. Why it matters: For redemption/deadline tracking, the filing pins the mandatory liquidation date and trust value: if no deal closes by October 31, 2026, public shareholders are to receive trust proceeds and the warrants expire worthless. It also discloses only $618,759 of cash outside trust and says its liquidity condition raises substantial doubt about going concern, while the filing's March 31, 2025 redemption value is $10.13 per share, not $10.63. The company remains a shell with no identified target.

What changed: A Joint Filing Agreement pursuant to Rule 13d-1(k) attached to a Schedule 13G beneficial ownership report. The document contains no updates to redemption deadlines, trust value per share, extension mechanics, business combination deal progress, or sponsor conduct. It registers zero changes to these parameters. Why it matters: Beyond confirming routine regulatory compliance, the filing substantively identifies LMR Partners LLP, LMR PARTNERS Ltd, LMR Partners LLC, LMR Partners AG, LMR PARTNERS (DIFC) Ltd, LMR Partners (Ireland) Limited, Ben Levine, and Stefan Renold as the reporting parties. Executed by Shane Cullinane, Allyson Hanlon, Ben Levine, and Stefan Renold, the agreement attributes independent liability for completeness and accuracy of each signer’s data to the respective signatory and mandates that all future Schedule 13G amendments be filed collectively without redundant joint agreements. While the document contains no claims regarding customers, revenue, market size, strategy, technology, partnerships, litigation, or personnel, it serves as a baseline compliance record for this multi-entity fund complex ahead of the stated 2026-10-31 search deadline.

What changed: A Joint Filing Agreement dated May 14, 2025, executed by and among Stellar V Sponsor LLC, Prokopios (Akis) Tsirigakis, and George Syllantavos, consenting pursuant to Rule 13d-1(f) under the Securities Exchange Act of 1934 to collectively submit a single Schedule 13D statement covering beneficial ownership of SVCC shares. This exhibit modifies the administrative disclosure pathway rather than any economic or operational metric. It bundles the reporting obligations of three distinct parties into one joint submission, removing the requirement for separate individual ownership statements. The document contains zero references to adjustments in the shareholder redemption window, trust account payout calculations, extension voting procedures, target combination milestones, or alterations to sponsor fiduciary conduct. All previously established mechanical parameters remain untouched by this text. Why it matters: The document explicitly names the filing coalition: Stellar V Sponsor LLC, Prokopios (Akis) Tsirigakis (identified as President), and George Syllantavos. By executing this agreement, these parties establish joint liability and synchronized amendment protocols for any subsequent Schedule 13D filings related to the issuer. The text includes no assertions regarding customer backlogs, contracted revenue, total addressable market valuations, business model strategies, patent portfolios, vendor alliances, active litigation, or executive turnover beyond the signatories. As a routine compliance attachment to a securities ownership report, it carries no direct impact on redemption pricing, deal progression timelines, or capital allocation decisions, though it definitively maps the unified disclosure entity that will track and publicly report any future equity movements.